Cytogen Corporation

Rutgers, The State University of New Jersey

Actinobac Biomed, Inc.

Other

Elan Corporation, Plc

Benjamin A Belinka, Jr

Daniel J Coughlin

Vernon L Alvarez

Richard Wood

Daniel Joseph O'Mahony

Scott Kachlany

Imelda Lambkin

Gerard M Cagney

Catherine A Patterson

Judith Singleton

John M Carter

Scott C Kachlany

This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.

Method of treating autoimmune inflammatory crohn's disease

Treatment and diagnosis of inflammatory disorders and HIV

This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the lumenal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastrointestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the lumenal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

The invention relates to a method of treating a patient in need thereof, including a need for diagnosis or treatment, comprising the administration of a metal complex of a polypeptide construct. The construct comprises a compound of the formula (I): ##STR1## in which, 'B' is a hydrocarbon backbone,

Treatment methods using metal-binding targeted polypeptide constructs

This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both metal-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of the formula (I): ##STR1## in which, 'B' is a hydrocarbon backbone, 'P' is a polypeptide capable of targeting particular cells, tissues or organs of the body, 'A' may be the group --NR'--NR'-- or the group --NR'--NR'--L-- in which L may be an aliphatic or aromatic linker group, R, R', and R' may be the same or different and may be hydrogen or an aliphatic group, m is an integer.gtoreq.2, provided that the groups R, R', R', L and 'P' of a given chain may be the same or different from the groups R, R', R', L and 'P' of another chain, n is an integer.gtoreq.0; or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.

Metal-binding targeted polypeptide constructs

Substituted thioureas as bifunctional chelators

This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both metal-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of the formula (I): ##STR1## in which, 'B' is a hydrocarbon backbone, 'P' is a polypeptide capable of targeting particular cells, tissues or organs of the body, 'A' may be the group --NR'--NR'-- or the group --NR'-- NR'--L-- in which L may be an aliphatic or aromatic linker group, R, R', and R' may be the same or different and may be hydrogen or an aliphatic group, m is an integer.gtoreq.2, provided that the groups R, R', R', L and 'P' of a given chain may be the same or different from the groups R, R', R', L and 'P' of another chain, n is an integer.gtoreq.0; or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.

This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, isothiocyanate derived thiocarbonyls for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.

Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal

A process for the purification of aminophosphonic acids under non-alkaline conditions is described. In particular, aminophosphonic acids are slurred in neutral or acidic water, heated to reflux, cooled and then filtered. Product purities approaching 100% are thus obtained.

Non-alkaline purification of aminophosphonic acids

This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both metal-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of the formula (I): ##STR1## in which, 'B' is a hydrocarbon backbone, 'P' is a polypeptide capable of targeting particular cells, tissues or organs of the body, 'A' may be the group --NR'--NR'-- or the group --NR'--NR'--L-- in which L may be an aliphatic or aromatic linker group, R, R' and R' may be the same or different and may be hydrogen or an aliphatic group, m is an integer .gtoreq.2, provided that the groups R, R', R', L and 'P' of a given chain may be the same or different from the groups R, R', R', L and 'P' of another chain, n is an integer .gtoreq.0; or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.

Growing community of inventors

Kendall Park, NJ, United States of America

Benjamin A Belinka, Jr